You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 133 No. 1, January 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Ocular Rosacea

Signs, Symptoms, and Tear Studies Before and After Treatment With Doxycycline

Mark J. Quarterman, MD; David W. Johnson, MD; Donald C. Abele, MD; Jack L. Lesher, Jr, MD; David S. Hull, MD; Loretta S. Davis, MD

Arch Dermatol. 1997;133(1):49-54.


Abstract

Objective
To examine ocular signs, symptoms, and results of tear analysis in patients with cutaneous rosacea before, during, and after doxycycline therapy.

Design
Before-after trial.

Setting
General community.

Patients or Other Participants
Thirty-nine patients with cutaneous rosacea underwent dermatologic and ocular examinations, testing of tear break-up time, and Schirmer testing at baseline and 4, 8, and 12 weeks. Six patients did not complete the study. Baseline tear break-up time and results of Schirmer test were compared with those of 13 patients without rosacea who were matched for age and sex.

Intervention
Patients with rosacea were given doxycycline, 100 mg daily for 12 weeks.

Main Outcome Measure
Statistically significant (P.05) improvement in tear break-up time.

Result
The most frequent ocular symptoms were dryness, itching, blurred vision, and photosensitivity, all of which improved significantly with treatment. All patients had signs of ocular disease, most commonly erythema and telangiectasia, meibomian gland dysfunction, and ciliary base injection. Significant improvement (P.05) for scales, erythema and telangiectasia, ciliary base injection, bulbar injection, papillary hypertrophy, and punctate epithelial erosions was seen. Average tear break-up time for the patients with rosacea was 5.7 seconds, which improved to 10.8 seconds after 12 weeks of treatment (P=.007). Baseline tear break-up time was significantly lower than for the comparison group of normal subjects (P=.001). There was no correlation between severity of cutaneous disease and ocular disease.

Conclusions
All patients with cutaneous rosacea had some degree of ocular involvement. Tear break-up time is abnormal in patients with rosacea. Ocular erythema and telangiectasia, meibomian gland dysfunction, and short tear break-up time in patients with cutaneous rosacea are indicators of ocular rosacea. Doxycycline, 100 mg daily, will improve ocular disease and increase the tear break-up time.

Arch Dermatol. 1997;133:49-54



Author Affiliations

From the Department of Medicine, Section of Dermatology (Drs Quarterman, Abele, Lesher, and Davis), and Department of Ophthalmology (Drs Johnson and Hull), Medical College of Georgia, Augusta. Dr Quarterman is now in private practice in Anderson, SC, and Dr Johnson is now in private practice in Woodstock, Ontario.


Footnotes

Deceased.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rosacea
Powell
NEJM 2005;352:793-803.
FULL TEXT  

Dry Eye Syndrome in Postmenopausal Women
Peterson et al.
JAMA 2002;287:585-586.
FULL TEXT  

Ocular Rosacea
Journal Watch Dermatology 1997;1997:9-9.
FULL TEXT  

Ocular Rosacea: Current Concepts and Therapy
Kligman
Arch Dermatol 1997;133:89-90.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.